HIV: GILEAD SCIENCES FILES FOR A SECOND NEW DRUG FOR FDA ASSESSMENT

California based company, Gilead Sciences has submitted to the Food  and Drug Administration (FDA) its investigational treatment for adults and children aged 12 years and above- two fixed dose combination of Gilead drugs, emtricitabine and Tenofoviralafenamide(F/TAF) for assessment.

Trials have shown that (F/TAF) is as effective as existing treatment Stribild (elvitegravir cobicistat tenofovir emtricitabine)

In clinical trial, the F/TAF combination has shown better renal and bone safety, high antiviral efficacy at adose less than one tenth of Gileads Viread (Tenofovir disoproxil fumarate-TDF).

This is Gilead Sciences' second F/TAF combination filing with FDA. It has a long history of innovating HIV treatments.

Gilead plans to submit a regulatory application for F/TAF to European Union in second quarter of 2015.

Culled from newsnow.co.uk